Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2014; 20(4): 899-907
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.899
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.899
How to select the optimal treatment for first line metastatic colorectal cancer
Alexander Stein, Carsten Bokemeyer, Department of Oncology, Haematology, Stem Cell Transplantation with the Section Pneumology, Hubertus Wald Tumor Centre University Cancer Centre Hamburg, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany
Author contributions: Both authors contributed equally to this work, designed and performed the research, analyzed the data, and wrote the paper.
Correspondence to: Alexander Stein, MD, Department of Oncology, Haematology, Stem Cell Transplantation with the Section Pneumology, Hubertus Wald Tumor Centre University Cancer Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. a.stein@uke.de
Telephone: +49-40-741056882 Fax: +49-40-741056744
Received: September 25, 2013
Revised: October 27, 2013
Accepted: December 12, 2013
Published online: January 28, 2014
Processing time: 123 Days and 15.1 Hours
Revised: October 27, 2013
Accepted: December 12, 2013
Published online: January 28, 2014
Processing time: 123 Days and 15.1 Hours
Core Tip
Core tip: Selection of the optimal first line treatment for metastatic colorectal cancer is a complex issue influencing course of disease and most likely survival of the individual patient. Available data will be analyzed to allow for a patient and disease specific, molecularly stratified treatment approach, applying systemic treatment (chemotherapy and antibodies) and locally ablative measures (surgery and radiofrequency ablation).